Bausch+Lomb Results Presentation Deck
3Q23 Total Bausch+Lomb P&L¹ (Non-GAAP)²
Reported
Change
9%
8%
1%
7%
8%
80 bps
(5%)
Bausch + Lomb
Vision Care Revenue³
Surgical Revenue
Pharmaceuticals Revenue ³
Total Revenue
Adj. Gross Profit²
Adj. Gross Margin²
Adj. R&D²
Adj. R&D % of Revenue
Adj. SG&A²
Adj. SG&A % of Revenue
Adj. EBITA²
Depreciation
Stock Based Compensation
Adj. EBITDA 2,4
Adj. EBITDA Margin²
Adj. Net Income Attributable to B+L²
Adj. EPS Attributable to B+L²
BAUSCH+ LOMB
3Q23
$648M
$185M
$174M
$1,007 M
$617M
61.3%
$81M
8.0%
$396M
39.3%
$140M
$35M
$16M
$187M
18.6%
3Q22
$597M
$172M
$173M
$942M
$570M
60.5%
$77M
8.2%
$360M
38.2%
$132M
$34M
$18M
$187M
19.9%
$107M
$0.31
(10%)
6%
3%
(11%)
0%
Constant Currency
Change²
11%
6%
1%
8%
10%
(29%)
(4%)
(10%)
14%
0%
(11%)
4%
3Q23 vs. 3Q22 Revenue:
(21%)
-$10M FX Headwinds
3Q23 vs. 3Q22 Adj. EBITDA²:
-$14M FX Headwinds
+7% Adj. EBITDA Growth Excluding FX²
$76M
$0.22
1. Products with sales outside the United States impacted by F/X changes.
2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.
3. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported
results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products.
The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
4. Includes transactional FX and NCI. FX headwinds were -$14M (-$7M translational and -$7M transactional) to Adj. EBITDA for 3Q23.
-$7M
Lynchburg
Disruptions
8View entire presentation